Preview

User

Not a user? Register with this site Forgot your password?

Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)

Advanced search

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy

https://doi.org/10.20340/vmi-rvz.2022.6.CASE.2

Abstract

This article is devoted to the discussion of cardioembolic complications of anthracycline cardiomyopathy. The article describes a clinical case of cardiotoxicity caused by aggressive neoadjuvant chemotherapy in a patient with breast cancer and complicated by the development of cardioembolic ischemic stroke.

About the Authors

G. R. Ramazanov
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


E. A. Kovaleva
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


R. A. Novikov
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


I. M. Kuz'mina
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


E. V. Klychnikova
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


L. T. Khamidova
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


N. V. Rybalko
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


A. M. Izmaylova
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation

Moscow


References

1. Shamalov N.A., Kustova M.A. Cryptogenic stroke. Neurology, neuropsychiatry, psychosomatics. 2014;( special issue 2):42-49 (In Russ). https://doi.org/10.14412/2074-2711-2014-2s-42-49

2. Bang O, Lee P, Joo S, Lee J, Joo I, Huh K. Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol. 2003;54(2):227-234. https://doi.org/10.1002/ana.10644

3. Gon Y, Okazaki S, Terasaki Y et al. Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016;3(4):280-287. https://doi.org/10.1002/acn3.291

4. Graus F, Rogers L, Posner J. Cerebrovascular Complications in Patients with Cancer. Medicine (Baltimore). 1985;64(1):16-35. https://doi.org/10.1097/00005792-198501000-00002

5. Chen P, Muo C, Lee Y, Yu Y, Sung F. Lung Cancer and Incidence of Stroke. Stroke. 2011;42(11):3034-3039. https://doi.org/10.1161/strokeaha.111.615534

6. Bang O, Chung J, Lee M, Seo W, Kim G, Ahn M. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. J Stroke. 2020;22(1):1-10. https://doi.org/10.5853/jos.2019.02278.

7. Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Inoue T. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(12):1336-1339. https://doi.org/10.1136/jnnp.2006.092940

8. Khorana A, Dalal M, Lin J, Connolly G. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2012;119(3):648-655. https://doi.org/10.1002/cncr.27772

9. Thompson C, Rodgers L. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci. 1952;223(5):469-478. https://doi.org/10.1097/00000441-195205000-00001

10. Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev. 2012;7(4):214-220. https://doi.org/10.2174/157340311799960645

11. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. The Lancet. 1992;339(8784). https://doi.org/10.1016/0140-6736(92)90139-t

12. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-1403. https://doi.org/10.1016/j.ejca.2012.12.027

13. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241. https://doi.org/10.3322/caac.21149

14. Ewer M, Ewer S. Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology. 2015;12(9):547-558. https://doi.org/10.1038/nrcardio.2015.65

15. Gendlin G.E., Emelina E.I., Nikitin I.G., etc. A modern view of the cardiotoxicity of chemotherapy of oncological levania, including anthracycline antibiotics. Russian Journal of Cardiology. 2017;3(143):145–154 (In Russ). https://doi.org/10.15829/1560-4071-2017-3-145-154

16. Armstrong G, Oeffinger K, Chen Y et al. Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer. Journal of Clinical Oncology. 2013;31(29):3673-3680. https://doi.org/10.1200/jco.2013.49.3205

17. Richardson AJ, Leckie T, Watkins ER et al. Post marathon cardiac troponin T is associated with relative exercise intensity. J Sci Med Sport. 2018;21(9):880-884. https://doi.org/10.1016/j.jsams.2018.02.005

18. Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012;23:vii155-vii166. https://doi.org/10.1093/annonc/mds293

19. Swain S, Whaley F, Ewer M. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869-2879. https://doi.org/10.1002/cncr.11407

20. Adams H, Bendixen B, Kappelle L et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. https://doi.org/10.1161/01.str.24.1.35

21. Pravdivtseva E.V., Poteshkina N.G., Svanadze A.M., etc. Prevention of the cardiotoxic effect of anthracycline anti-biotic doxorubicin: the role of an angiotensin-converting enzyme inhibitor perindopril. Clinician. 2011;5,3: 55-60 (In Russ).

22. Bosch X, Rovira M, Sitges M et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/j.jacc.2013.02.072

23. Kalay N, Basar E, Ozdogru I et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-2262. https://doi.org/10.1016/j.jacc.2006.07.052


Review

For citations:

Ramazanov G.R., Kovaleva E.A., Novikov R.A., Kuz'mina I.M., Klychnikova E.V., Khamidova L.T., Rybalko N.V., Izmaylova A.M. Ischemic stroke as the first manifestation of anthracycline cardiomyopathy. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2022;12(6):127-133. (In Russ.) https://doi.org/10.20340/vmi-rvz.2022.6.CASE.2

Views: 379


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2226-762X (Print)
ISSN 2782-1579 (Online)

227 Chapaevskaya St., Samara, 443001

Processing of personal data
supported by NEICON (Elpub lab)